Copyright: ©Author(s) 2026.
World J Cardiol. Jul 26, 2026; 18(7): 117872
Published online Jul 26, 2026. doi: 10.4330/wjc.117872
Published online Jul 26, 2026. doi: 10.4330/wjc.117872
Table 1 5-year outcomes of NeoHexa vs contemporary drug-eluting stents
| Stent system | Ref. | 5-year major adverse cardiac event | 5-year target lesion revascularization | Key feature |
| NeoHexa | Trehan et al[1] | 4.32% | 1.76% | Biodegradable polymer |
| Orsiro | BIOFLOW V | 8.0%-18.0% | 5.9% | Ultrathin struts (60 μm) |
| Ultimaster | CENTURY II | N/A | 9.4% | Bioresorbable coating |
| CYPHER | SORT OUT IV | 17.4% | N/A | Durable polymer |
| MiStent | DESSOLVE I/II | 15.1% | 3.5% | Crystalline sirolimus |
| XIENCE | SPIRIT II | 8.0%-15.0% | 4.0%-6.0% | Cobalt-chromium everolimus-eluting stents |
- Citation: Zhong JX, Rao XQ. NeoHexa stent at five years: Sirolimus power meets real-world endurance. World J Cardiol 2026; 18(7): 117872
- URL: https://www.wjgnet.com/1949-8462/full/v18/i7/117872.htm
- DOI: https://dx.doi.org/10.4330/wjc.117872